Joint Venture

Tummy Care Max

Overview

TummyCare Max established in October 2013 to help the 1 million babies born in the US each year that suffer painful and sometimes dangerous symptoms of baby acid reflux disease or baby GERD (Gastro-Esophageal Reflux Disease), currently a 1.2 Billion dollar industry projected to grow to $4.3 Billion by year 2025.

TummyCare Max LLC has an executed version of TummyCare Max®(pending FDA clearance); a pre-formulated compound specifically made to blend infant reflux medications that make treatment favorable in flavor, immediate acting, most beneficial for supplementation of nutrients that may be compromised by treatment and is extremely gentle to a baby’s sensitive digestive system.

Based on a product formulated during the MarciKids study which started at the University of Missouri in the early 1990s, this product has a 25 year successful treatment history that has created a raving fan customer base that’s carried on over time.

Request additional Information

Interested in this Investment Offering? Complete the form below for additional information.